Cardiology Conference: “Practice-Changing” Data On Device Interventions
This article was originally published in The Gray Sheet
Late-breaking clinical trials of coronary stent and related interventions are bringing both practice-changing and surprising results, according to physicians who attended a major cardiology meeting in Chicago last week
You may also be interested in...
Bausch & Lomb gets approval for first-of-a-kind intraocular lens. Roche HbA1c assay is first to be cleared to diagnose diabetes. More product launches and approvals from the past week.
Drug-coated angioplasty balloon: Percutaneous treatment of femoropopliteal disease with paclitaxel-coated angioplasty balloons was associated with reduced six-month lumen loss and target-lesion revascularization rates compared to regular angioplasty balloons in the 154-patient randomized THUNDER trial sponsored by Bavaria Medizintechnologie and Schering. Results appear in the Feb. 14 issue of the New England Journal of Medicine. THUNDER is a small preliminary study and larger trials are needed to confirm the benefits of drug-coated balloons, according to authors Gunnar Tepe, M.D., University of Tübingen, et al
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.